This activity will review the current recommendations for screening and vaccination in both organ donors and organ recipients and will examine the current rationale and value of measuring COVID-19 antibody titers in light of possible low posttransplant sero-response and humoral response rates. Importantly, the current state of, and future implications for, transplantation in nonvaccinated patients will be discussed.

This activity will help participants to better determine the role and optimal timing of liver transplant in ACLF. It will review precipitators of ACLF associated with poorer outcomes, including bacterial infections and hepatitis B virus, and will explore posttransplant outcomes and predictors. The accuracy of current scoring systems for assessing the severity of disease and predicting survival will be discussed, including the Model for End-stage Liver Disease (MELD) score and the Chronic Liver Failure Consortium Organ Failure (CLIF-C OF) score.

Throughout these activities, faculty will discuss the keys to optimize the management/benefits of individuals undergoing organ or blood/marrow transplant. Participants will learn about advances, trends and updates on relevant topics within this field.

This activity will provide an overview of the living-donor liver transplant procedure, the advantages and disadvantages of living-donor liver transplant, and the optimal timing for offering living donations to patients with liver cancer. Dr. Hughes will discuss the innovative approach advanced by experts at UPMC in which patients with liver cancer are offered the option of a living-donor transplant. He will discuss the experience and expertise offered by the UPMC Liver Transplant Program and their collaborative approach to working with referring physicians.